Beast Ventures

Baseimmune is a biotech startup focused on developing the next generation of vaccines. The company has created a platform for pathogen analysis that facilitates the design of antigens and vaccines. Utilizing advanced technology, Baseimmune's platform enables the generation of antigens with a high level of informatics depth, allowing for effective responses to emerging and challenging pathogens. This capability ensures that healthcare providers can maintain vaccine efficacy even in the face of pathogen mutations.

Nutropy is a producer of innovative milk ingredients that replicate those found in cow's milk, aimed at creating premium cheese alternatives. By utilizing microbes and fermentation processes, the company manufactures dairy proteins comparable to those derived from cows, allowing for the development of cheese products that maintain a similar taste and texture to traditional cheese. This approach not only offers a sustainable solution by eliminating the need for animal involvement but also addresses health and environmental concerns associated with conventional dairy production. Nutropy's technology enables businesses to scale cheese alternatives for the global market while significantly reducing their carbon footprint.

Baseimmune is a biotech startup focused on developing the next generation of vaccines. The company has created a platform for pathogen analysis that facilitates the design of antigens and vaccines. Utilizing advanced technology, Baseimmune's platform enables the generation of antigens with a high level of informatics depth, allowing for effective responses to emerging and challenging pathogens. This capability ensures that healthcare providers can maintain vaccine efficacy even in the face of pathogen mutations.

Q Bio, founded in 2015 by Jeffrey Kaditz, Dr. Michael Snyder, and Dr. Garry Choy, operates a clinical digital twin platform aimed at assessing patients' medical histories to identify immediate and future health risks. Based in San Carlos, California, the company utilizes whole-body scans to create a digital twin of each patient's physical body, quantifying and digitizing health data. By leveraging simulated human physiology and machine learning, Q Bio's platform can predict potential health risks, enabling healthcare professionals to provide proactive treatment. The interdisciplinary team at Q Bio comprises experts in applied mathematics, computational physics, electrical engineering, genetics, and radiology, supported by prominent venture capital firms.

Clear Labs, Inc. is a food analytics company based in Menlo Park, California, founded in 2013. The company specializes in providing a comprehensive analytics platform that analyzes the molecular contents of food and ingredients. Its offerings include Clear Dx™ and Clear Safety™, which utilize next-generation sequencing and data analytics for food safety testing and infectious disease surveillance. Clear Labs serves food manufacturers, suppliers, and retailers by ensuring transparency throughout the supply chain and testing products for various factors such as authenticity, contamination, allergens, and nutritional content. The platform delivers actionable insights that enhance safety and operational efficiency while supporting public health initiatives. Through its integrated genomics system, Clear Labs aims to simplify complex diagnostics across clinical and applied markets, making genomic insights accessible to labs, hospitals, and businesses.

LabGenius Ltd is a biopharmaceutical company based in London that focuses on discovering new biological molecules through the integration of artificial intelligence, automation, and synthetic DNA. Founded in 2012, the company has developed a robotic platform known as EVA, which acts as a robot scientist capable of designing, conducting, and learning from its own experiments. LabGenius specializes in developing next-generation protein therapeutics aimed at addressing unmet medical needs, including conditions like Inflammatory Bowel Disease. Their innovative approach utilizes advanced machine learning and synthetic biology to engineer the properties of protein drugs, enhancing attributes such as protease stability and tissue penetration. This technology enables the efficient creation of protein therapeutics, providing physicians with access to cutting-edge treatments developed through robotic automation.

Sparrho operates a discovery platform designed to make scientific information more accessible. The platform aggregates, distills, and recommends relevant content from various sources, including journals, patents, and conferences. It provides customized and filtered recommendations, allowing users to add content, save discoveries, and share findings. Founded in 2013 by two Oxbridge scientists, Sparrho emerged from a need for more effective literature search tools. The company is headquartered in London, United Kingdom, and serves a diverse clientele, including Fortune 500 companies worldwide. By leveraging a combination of artificial intelligence and expert input, termed Augmented Intelligence, Sparrho aims to enhance the way scientific research is curated and consumed.

Q Bio, founded in 2015 by Jeffrey Kaditz, Dr. Michael Snyder, and Dr. Garry Choy, operates a clinical digital twin platform aimed at assessing patients' medical histories to identify immediate and future health risks. Based in San Carlos, California, the company utilizes whole-body scans to create a digital twin of each patient's physical body, quantifying and digitizing health data. By leveraging simulated human physiology and machine learning, Q Bio's platform can predict potential health risks, enabling healthcare professionals to provide proactive treatment. The interdisciplinary team at Q Bio comprises experts in applied mathematics, computational physics, electrical engineering, genetics, and radiology, supported by prominent venture capital firms.